× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy


× Important note: This Web site presents preliminary results. We are working non-stop to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 2

Bivalirudin

colchicine 1

face mask

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies 1

IFX-1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs

sodium aescinate

Apilimod

corticosteroids 7

ciclesonide

dexamethasone 1

inhaled steroids

low-dose corticosteroids

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment 7

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

Interleukin-2

rhG-CSF

vaccines

BCG vaccination

Immunosuppressants drugs

anakinra

eculizumab

interleukin-6 inhibitor

clazakizumab

sarilumab 1

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab 10

jakotinib

lenzilumab

ruxolitinib

tacrolimus

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiviral and associated therapy

ASC09/ritonavir

azithromycin 1

azvudine

baloxavir marboxil

bromhexine

carrimycin

chloroquine and derivatives 5

chloroquine 1

hydroxychloroquine 13

hydroxychloroquine 600mg 1

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

favipiravir 1

fluvoxamine

hydroxychloroquine plus macrolides 6

interferon

SNG001 inhaled interferon beta 1

ivermectin

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 3

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b

meplazumab

oseltamivir plus chloroquin

remdesevir 2

Renin-angiotensin-system-acting agents 7

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

RAS blocker withdrawal

rhACE2

ritonavir

tranexamic acid

triazavirin

umifenovir (arbidol) 1

control

prone positioning

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

DPP-4 inhibitor

enoxaparin

levamisole

natural killer (NK) cells

nicotin

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

pamrevlumab

PUL-042 inhalation solution

selinexor

stem cells

tradipitant

tranilast

Latest studies

COVACTA unpublished   NCT04320615 10 days ago

tocilizumab vs. placebo - COVID-19 severe or critically low risk of bias

    COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality

  • inconclusive results for: clinical improvement

meta-analysis

Mitja , 2020   NCT04304053 2 weeks ago

hydroxychloroquine vs. control - COVID-19 prophylaxis some concern in risk of bias

  • inconclusive results for: death; PCR-confirmed, symptomatic Covid-19 disease

meta-analysis

Coalition Covid-19 Brazil I , 2020   NCT04322123 2 weeks ago

hydroxychloroquine plus macrolides vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

  • inconclusive results for: 15 days clinical worsening (7 levels ordinal scale); in hospital deaths

meta-analysis

Coalition Covid-19 Brazil I , 2020   NCT04322123 2 weeks ago

hydroxychloroquine vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

  • inconclusive results for: 15 days clinical worsening (seven-point ordinal scale); death

meta-analysis

SNG001 inhaled interferon beta vs. placebo - COVID 19 hospitalized NA risk of bias

  • suggested 2.2-fold increase in recovery
  • suggested 79 % decrease in 16-day ventilation or death

risk of bias not assessable

meta-analysis

Skipper , 2020   NCT04308668 3 weeks ago

hydroxychloroquine 600mg vs. placebo - COVID 19 outpatients some concern in risk of bias

    change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)

  • inconclusive results for: no ongoing symptoms at 14 days; deaths

meta-analysis

RECOVERY , 2020   5 weeks ago

lopinavir/ritonavir vs. control - COVID 19 hospitalized some concern in risk of bias

    the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm

  • inconclusive results for: 28-day mortality

meta-analysis

Arshad (HCQ) , 2020   OBS 5 weeks ago

hydroxychloroquine vs. control - COVID 19 hospitalized critical risk of bias

  • suggested 66 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

Arshad (HCQ AZ) , 2020   OBS 5 weeks ago

hydroxychloroquine plus macrolides vs. control - COVID 19 hospitalized critical risk of bias

  • suggested 71 % decrease in mortality but with a very low degree of certainty due to critical risk of bias

meta-analysis

GRECCO-19 , 2020   NCT04326790 2 months ago

colchicine vs. standard of care - COVID 19 hospitalized some concern in risk of bias

  • suggested 89 % decrease in clinical deterioration

meta-analysis

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons